Advertisement

Prognosis and therapy of myelodysplastic syndromes

  • Elihu H. Estey
Part of the Cancer Treatment and Research book series (CTAR, volume 64)

Abstract

This chapter will deal primarily with issues faced by physicians in the management of patients with myelodysplastic syndromes (MDSs). Accordingly, emphasis will be placed on assessing these patients’ prognoses and the therapeutic options available in light of these prognoses.

Keywords

Myelodysplastic Syndrome Normal Karyotype Cytogenetic Abnormality Refractory Anemia Abnormal Karyotype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett JM, Catovsky D, Daniel MT, et al. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 626–629.Google Scholar
  2. 2.
    Rheingold JJ, Kaufman R, Adelson E, Lear A (1963). Smoldering acute leukemia. N Engl J Med 268: 812–815.PubMedCrossRefGoogle Scholar
  3. 3.
    Rheingold JJ (1974). Acute leukemia, its smoldering phase or Leukemia never starts on Thursday. JAMA 230: 985–986.PubMedCrossRefGoogle Scholar
  4. 4.
    Mufti GJ, Stevens JR, Oscier DG, et al. (1985). Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425–433.PubMedCrossRefGoogle Scholar
  5. 5.
    Sanz GH, Sanz MA, Vallespi T, et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74: 395–408.PubMedGoogle Scholar
  6. 6.
    Bennett JM, Catovsky D, Daniel MT, et al. (1976). Proposals for the classification of the acute leukaemias. Br J Haematol 33: 451–458.PubMedCrossRefGoogle Scholar
  7. 7.
    Foucar K, Langdon RM, Armitage JO, et al. (1985). Myelodysplastic syndromes: A clinical and pathologic analysis of 109 cases. Cancer 56: 553–561.PubMedCrossRefGoogle Scholar
  8. 8.
    Vallespi T, Torrabadella M, Julia A, et al. (1985). Myelodysplastic syndromes: a study of 101 cases according to the FAB Classification. Br J Haematol 61: 83–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Jacobs RH, Cornbleet MA, Vardiman JW, et al. (1986). Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67: 1765–1772.PubMedGoogle Scholar
  10. 10.
    Kerkhofs H, Hermans J, Haak HL, et al. (1987). Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65: 73–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Varela BL, Chuang C, Bennett JM (1982). Clinical significance of the new proposals for the classication of the myelodysplastic syndromes. Blood 60(Suppl 1):140e (abstract).Google Scholar
  12. 12.
    van der Weide M, Sizoo W, Nauta JJP, et al. (1980). Myelodysplastic syndromes: analysis of clinical and prognostic features in 96 patients. Eur J Haematol 41: 115–122.CrossRefGoogle Scholar
  13. 13.
    Coiffier B, Adeleine P, Gentilhomme O, et al. (1987). Myelodysplastic syndromes: A multiparametric study of prognostic factors in 336 patients. Cancer 60: 3029–3032.PubMedCrossRefGoogle Scholar
  14. 14.
    Maddox AM, Keating MJ, Smith TL, et al. (1986). Prognostic factors for survival of 194 patients with low infiltrate leukemia. Leuk Res 10: 995–1006.PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshida Y, Oguma S, Uchino M (1991). Long-term survival of refractory myelodysplastic anemias. N Engl J Med 325: 662.PubMedGoogle Scholar
  16. 16.
    Tricot G, Boogaerts MA, DeWolf-Peeters C, et al. (1985). The myelodysplastic syndromes: different evolution patterns based on morphological and cytogenetic investigations. Br J Haematol 59: 659–670.PubMedCrossRefGoogle Scholar
  17. 17.
    Borgström GH (1986). Cytogenetics of the myelodysplastic syndromes. Scand J Haematol 36(Suppl 45):74–77.Google Scholar
  18. 18.
    Weh HJ, Calavezos A, Seeger D, et al. (1987). Cytogenetics studies in 69 patients with myelodysplastic syndromes (MDS). Eur J Hamatol 38: 166–172.CrossRefGoogle Scholar
  19. 19.
    Knapp RH, Dewald GW, Pierre RV (1985). Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes: Mayo Clin Proc 60: 507–516.PubMedGoogle Scholar
  20. 20.
    Yunis JJ, Lobell M, Arnesen MA, et al. (1988). Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 68: 189–194.PubMedCrossRefGoogle Scholar
  21. 21.
    Pierre RV, Catovsky D, Jufti GJ, et al. (1989). Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40: 149–161.PubMedCrossRefGoogle Scholar
  22. 22.
    Bloomfield CD (1986). Chromosome abnormalities in secondary myelodysplastic syndromes. Scand J Haematol 36(Suppl 45):82–90.Google Scholar
  23. 23.
    Van den Berghe H (1986). The 5q-syndrome. Scand J Haematol 36(Suppl 45):78–81.Google Scholar
  24. 24.
    Estey EH, Keating MJ, Dixon DO, et al. (1987). Karyotype is prognostically more important than the FAB system’s distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol 1: 203–208.PubMedGoogle Scholar
  25. 25.
    Raymakers R, DeWitte T, Joziasse J, et al. (1991). In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemia. Br J Haematol 78: 35–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Galton DAG (1986). The myelodysplastic syndromes. Scand J Haematol 36(Suppl 45):11–20.Google Scholar
  27. 27.
    Elias L, Hoffman R, Boswell S, et al. (1987). A trial of recombinant α2 interferon in the myelodysplastic syndromes: 1. Clinical results. Leukemia 1: 105–110.Google Scholar
  28. 28.
    Freireich E, Gehan E, Sulman D, et al. (1961). The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14: 593–608.PubMedCrossRefGoogle Scholar
  29. 29.
    Hong WK, Lippman SM, Itri L, et al. (1990). Prevention of second primary tumors with isotretinon in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795–801.PubMedCrossRefGoogle Scholar
  30. 30.
    Warrell RP, Frankel SR, Miller WH, et al. (1991). Differentiation therapy of acute promyelocytic leukemia with tretinoin (All-trans-retinoic acid). N Engl J Med 324: 1385–1393.PubMedCrossRefGoogle Scholar
  31. 31.
    Muindi J, Frankel SR, Miller WH, et al. (1992). Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid ‘resistance’ in patients with acute promyelocytic leukemia. Blood 79: 299–303.PubMedGoogle Scholar
  32. 32.
    Breitman TR, Selonick SE, Collins SJ (1980). Induction of differentiation of the human promyelocytic leukemia cell line (HL60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936.PubMedCrossRefGoogle Scholar
  33. 33.
    Gold EJ, Mertelsmann RH, Itri LM, et al. (1983). Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep 67: 981–986.PubMedGoogle Scholar
  34. 34.
    Greenberg BR, Durie BGM, Barnett TC, et al. (1985). Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep 69: 1369–1374.PubMedGoogle Scholar
  35. 35.
    Abrahm J, Besa EC, Hyzinski M, et al. (1986). Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic symdrome: inhibition of growth of the patient’s malignant monocytoid clone. Blood 67: 1323–1327.PubMedGoogle Scholar
  36. 36.
    Picozzi VJ, Swanson GF, Morgan R, et al. (1986). 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 4: 589–595.PubMedGoogle Scholar
  37. 37.
    Kerndrup G, Bendix-Hansen K, Pedersen B, et al. (1987). 13-cis retinoic acid treatment of myleodysplastic syndromes. Leuk Res 11: 7–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Clark RE, Lush CH, Jacobs A, et al. (1987). Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1: 763–765.PubMedCrossRefGoogle Scholar
  39. 39.
    Koeffler HP, Heitjan D, Mertelsmann R, et al. (1988). Randomized study of 13-cis-retinoic acid v placebo in the myelodysplastic disorders. Blood 71: 703–708.PubMedGoogle Scholar
  40. 40.
    Vadhan-Raj S, Keating M, LeMaistre A, et al. (1987). Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552.PubMedCrossRefGoogle Scholar
  41. 41.
    Ganser A, Völkers B, Greher J, et al. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes—a phase I-II trial. Blood 73: 31–37.PubMedGoogle Scholar
  42. 42.
    Thompson JA, Lee DJ, Kidd P, et al. (1989). Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7: 629–637.PubMedGoogle Scholar
  43. 43.
    Estey E, Kurzrock R, Talpaz M, et al. (1989). Therapy of myelodysplastic syndromes (MDS) with GM-CSF. Proc ASCO 8: 200 (abstract).Google Scholar
  44. 44.
    Estey E, Kurzrock R, Talpaz M, et al. (1991). Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77: 291–295.PubMedCrossRefGoogle Scholar
  45. 45.
    Antin JH, Smith BR, Holmes W, et al. (1988). Phase I-II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72: 705–713.PubMedGoogle Scholar
  46. 46.
    Herrmann F, Lindemann A, Klein H, et al. (1989). Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 3: 335–338.PubMedGoogle Scholar
  47. 47.
    Estey E, Thall PF, Kantarjian H, et al. (1992). Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79: 2246–2255.PubMedGoogle Scholar
  48. 48.
    Schuster AA, Thompson JA, Larson R, et al. (1990). Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients with myelodysplastic syndrome or aplastic anemia. Proc ASCO 9: 205.Google Scholar
  49. 49.
    Negrin RS, Haeuber DH, Nagler A, et al. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 110: 976–984.PubMedGoogle Scholar
  50. 50.
    Negrin RS, Haeuber DH, Nagler A, et al. (1990). Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43.PubMedGoogle Scholar
  51. 51.
    Kobayashi Y, Okabe T, Ozawa K, et al. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary report. Am J Med 86: 178–182.PubMedCrossRefGoogle Scholar
  52. 52.
    Yoshida Y, Hirashima H, Asano S, et al. (1991). A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78: 378–384.PubMedCrossRefGoogle Scholar
  53. 53.
    Ganser A, Seipelt G, Lindemann A, et al. (1990). Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76: 455–462.PubMedGoogle Scholar
  54. 54.
    Kurzrock R, Talpaz M, Estrov Z, et al. (1991). Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9: 1241–1250.PubMedGoogle Scholar
  55. 55.
    Eschbach JW, Egrie JC, Downing MR, et al. (1987). Correct of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 316: 73.PubMedCrossRefGoogle Scholar
  56. 56.
    Stein RS, Abels RI, Krantz SB (1991). Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78: 1658–1663.PubMedGoogle Scholar
  57. 57.
    Kurzrock R, Talpaz M, Estey E, et al. (1991). Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 5: 985–990.PubMedGoogle Scholar
  58. 58.
    Kanz L, Brugger W, Bross K, et al. (1991). Combination of cytokines: current status and future prospects. Br J Haematol 79(Suppl 1):96–104.PubMedCrossRefGoogle Scholar
  59. 59.
    Berry DA (1987). Interim analysis in clinical trials: the role of the likelihood principle. Am Statistician 41: 117–122.Google Scholar
  60. 60.
    Wisch JS, Griffin JD, Kufe DW (1983). Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599–1602.PubMedCrossRefGoogle Scholar
  61. 61.
    Bolwell BJ, Cassileth PA, Gale RP (1987). Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1: 575–579.PubMedGoogle Scholar
  62. 62.
    Cheson BD, Jasperse DM, Simon R, et al. (1986). A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–1864.PubMedGoogle Scholar
  63. 63.
    Mertelsmann R, Thaler HT, To L (1980). Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56: 773–781.PubMedGoogle Scholar
  64. 64.
    Armitage JO, Dick FR, Needleman SW, et al. (1981). Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65: 601–605.PubMedGoogle Scholar
  65. 65.
    Tricot G, Boogaerts MA (1986). The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63: 477–483.PubMedCrossRefGoogle Scholar
  66. 66.
    Preisler HD, Raza A, Barcos M, et al. (1986). High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. Am J Hematol 23: 131–134.PubMedCrossRefGoogle Scholar
  67. 67.
    Fenaux P, Lai JL, Jouet JP, et al. (1988). Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57: 297–302.PubMedCrossRefGoogle Scholar
  68. 68.
    Fenaux P, Morel P, Rose C, et al. (1991). Prognostic factors in adult de novo myelodysplastic syndromes treated by intestive chemotherapy. Br J Haematol 77: 497–501.PubMedCrossRefGoogle Scholar
  69. 69.
    Michels SD, Saumur J, Arthur DC, et al. (1989). Refractory anemia with excess of blasts in transformation-hematologic and clinical study of 52 patients. Cancer 64: 2340–2346.PubMedCrossRefGoogle Scholar
  70. 70.
    Appelbaum FR, Barrall J, Storb R (1990). Bone marrow transplantation for patients with myelodysplasia: pretreatment variables and outcome. Ann Intern Med 590–597.Google Scholar
  71. 71.
    O’Donnell MR, Nademanee AP, Snyder DS, et al. (1987). Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5: 1822–1826.PubMedGoogle Scholar
  72. 72.
    Belanger R, Gyger M, Perreault C, et al. (1988). Bone marrow transplantation for myelodysplastic syndromes. Br J Haematol 69: 29–33.PubMedCrossRefGoogle Scholar
  73. 73.
    DeWitte T, Zwaan F, Herman J, et al. (1989). Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Bone Marrow Transplant (Suppl 3):38–39.Google Scholar
  74. 74.
    Bunin NJ, Casper JT, Chitambar C, et al. (1988). Partially matched bone marrow transplantation in patients with myelodsplastic syndromes. J Clin Oncol 6: 1851–1855.PubMedGoogle Scholar
  75. 75.
    Clift RA, Buckner CD, Thomas ED, et al. (1987). The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2: 243–258.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Elihu H. Estey

There are no affiliations available

Personalised recommendations